Patients were selected from the observational BiOCURA study in which patients were enrolled between 2009 and 2015. Serum samples from selected subjects were measured on three targeted LC-MS platforms,
Association between the M-CHARTS score 12 months after initiating intravitreal ranibizumab therapy and baseline parameters in eyes with branch retinal vein occlusion.
